These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 3707802)

  • 41. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane.
    Snoeck MM; Gielen MJ; Tangerman A; van Egmond J; Dirksen R
    Acta Anaesthesiol Scand; 2000 Mar; 44(3):334-7. PubMed ID: 10714850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia.
    Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyfort GH; Dupuis BA
    Br J Anaesth; 1990 Jan; 64(1):64-6. PubMed ID: 2302378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia-susceptible patients.
    Wappler F; Scholz J; Oppermann S; von Richthofen V; Steinfath M; Schulte am Esch J
    J Clin Anesth; 1997 Jun; 9(4):306-11. PubMed ID: 9195354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the caffeine skinned fibre tension (CSFT) test with the caffeine-halothane contracture (CHC) test in the diagnosis of malignant hyperthermia.
    Britt BA; Frodis W; Scott E; Clements MJ; Endrenyi L
    Can Anaesth Soc J; 1982 Nov; 29(6):550-62. PubMed ID: 7139394
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.
    Weglinski MR; Wedel DJ; Engel AG
    Anesth Analg; 1997 May; 84(5):1038-41. PubMed ID: 9141928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
    Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
    Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abnormal action potential responses to halothane in heart muscle isolated from malignant hyperthermia-susceptible pigs.
    Roewer N; Greim C; Rumberger E; Schulte am Esch J
    Anesthesiology; 1995 Apr; 82(4):947-53. PubMed ID: 7717567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The in vitro determination of susceptibility to malignant hyperthermia.
    Iaizzo PA; Lehmann-Horn F
    Muscle Nerve; 1989 Mar; 12(3):184-90. PubMed ID: 2725548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs.
    Schuster F; Schöll H; Hager M; Müller R; Roewer N; Anetseder M
    Anesth Analg; 2006 Feb; 102(2):468-72. PubMed ID: 16428544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diltiazem and nifedipine reduce the in vitro contracture response to halothane in malignant hyperthermia-susceptible muscle.
    Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Reyford HG; Adamantidis MM; Dupuis BA
    Can J Anaesth; 1990 Jul; 37(5):556-9. PubMed ID: 2372858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.
    Larach MG
    Anesth Analg; 1989 Oct; 69(4):511-5. PubMed ID: 2675676
    [No Abstract]   [Full Text] [Related]  

  • 52. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
    Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
    Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spectrum of susceptibility to malignant hyperthermia--diagnostic dilemma.
    Nelson TE; Flewellen EH; Gloyna DF
    Anesth Analg; 1983 Jun; 62(6):545-52. PubMed ID: 6846875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility.
    Weigl LG; Ludwig-Papst C; Kress HG
    Anesth Analg; 2004 Jul; 99(1):103-107. PubMed ID: 15281512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diltiazem inhibits halothane-induced contractions in malignant hyperthermia-susceptible muscles in vitro.
    Ilias WK; Williams CH; Fulfer RT; Dozier SE
    Br J Anaesth; 1985 Oct; 57(10):994-6. PubMed ID: 4041327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Tests of contracture and sensitivity to malignant hyperthermia in 27 patients].
    Krivosic-Horber R; Adnet P; Krivosic I; Theunynck D; Guévart E; Adamantidis M
    Ann Fr Anesth Reanim; 1988; 7(2):132-8. PubMed ID: 3364812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of the calcium antagonist, TMB-8 on halothane and on caffeine contractures of malignant hyperthermia susceptible skeletal muscle.
    Williams JH; Holland M; Lee JC
    Res Commun Chem Pathol Pharmacol; 1990 Jun; 68(3):387-90. PubMed ID: 2385762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [In vitro diagnosis of malignant hyperpyrexia syndrome].
    Eldar I; Goldberg G; Glauber V; Perel A
    Harefuah; 1991 Dec; 121(12):499-502. PubMed ID: 1794753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.